Predicting therapeutic response through biomarker analysis in psoriatic arthritis, an example of precision medicine

References

• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212.
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.e19.
   PubMed Web of Science ®Google Scholar
• Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(5):405–417.
   PubMed Web of Science ®Google Scholar
• Chandran V, Scher JU. Biomarkers in psoriatic arthritis: recent progress. Curr Rheumatol Rep. 2014;16(11):453.
   PubMed Web of Science ®Google Scholar
• So A, Inman RD. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):453–471.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015;27(2):127–133.
   PubMed Web of Science ®Google Scholar
• Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;(4):CD005468.DOI: 10.1002/14651858.CD005468.pub2.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013;65(5):1213–1223.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Crown J. Companion biomarkers: paving the pathway to personalized treatment for cancer. Clin Chem. 2013;59(10):1447–1456.
   PubMed Web of Science ®Google Scholar
• Jameson JL, Longo DL. Precision medicine–personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–2234.
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Rocha Trocoli Drakensjö I, Girnita A. Personalized medicine in malignant melanoma: towards patient tailored treatment. Front Oncol. 2018;8:202.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–1696.
   PubMed Web of Science ®Google Scholar
• Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32(3):181–201.
   PubMed Web of Science ®Google Scholar
• Brandrup F, Holm N, Grunnet N, et al. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol. 1982;62(3):229–236.
   PubMed Web of Science ®Google Scholar
• Chandran V, Schentag CT, Brockbank JE, et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis. 2009;68(5):664–667.
   PubMed Web of Science ®Google Scholar
• Okada Y, Han B, Tsoi LC, et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet. 2014;95(2):162–172.
   PubMed Web of Science ®Google Scholar
• Stuart PE, Tsoi LC, Hambro CA, et al. 2018. Genetics of Psoriasis, oxford textbook of psoriatic arthritis. Oxford University Press, New York, USA: Eds Fitzgerald and Gladman.
   Google Scholar
• Winchester R, O’Rielly D, Rahman P. 2018. Genetics of psoriatic arthritis, oxford textbook of psoriatic arthritis. Oxford University Press, New York, USA: Eds Fitzgerald and Gladman.
   Google Scholar
• O’Rielly DD, Jani M, Rahman P, et al. The genetics of psoriasis and psoriatic arthritis. J Rheumatol Suppl. 2019;95:46–50.
   PubMedGoogle Scholar
• Aterido A, Cañete JD, Tornero J, et al. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. Ann Rheum Dis. 2019;78(3):e214158.
   PubMed Web of Science ®Google Scholar
• Cascella R, Strafella C, Ragazzo M, et al. KIF3A and IL-4 are disease-specific biomarkers for psoriatic arthritis susceptibility. Oncotarget. 2017;8(56):95401–95411.
   PubMedGoogle Scholar
• Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–2284.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Benjamin M, Tan AL. The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? Curr Opin Rheumatol. 2009;21(4):340–347.
   Google Scholar
• Vandooren B, Noordenbos T, Ambarus C, et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum. 2009;60(4):966–975.
   PubMedGoogle Scholar
• Spadaro A, Scrivo R, Moretti T, et al. Natural killer cells and gamma/delta T cells in synovial fluid and in peripheral blood of patients with psoriatic arthritis. Clin Exp Rheumatol. 2004;22(4):389–394.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359(1–2):419–429.
   PubMed Web of Science ®Google Scholar
• Al-Mossawi MH, Chen L, Fang H, et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nat Commun. 2017;8(1):1510.
   PubMedGoogle Scholar
• Abji F, Pollock RA, Liang K, et al. Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis. Clin Exp Rheumatol. 2018;36(3):486–489.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–1076.
   PubMed Web of Science ®Google Scholar
• Adamopoulos IE, Tessmer M, Chao CC, et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol. 2011;187(2):951–959.
   PubMed Web of Science ®Google Scholar
• Colucci S, Brunetti G, Cantatore FP, et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol. 2007;212(1):47–55.
   PubMed Web of Science ®Google Scholar
• Weitzmann MN. Bone and the Immune System. Toxicol Pathol. 2017;45(7):911–924.
   PubMed Web of Science ®Google Scholar
• Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65–70.
   PubMed Web of Science ®Google Scholar
• Ettore S, Alessandra B, Giovanni C, et al. Biological and synthetic target DMARDs in psoriatic arthritis. Pharmacol Res. 2019;104473. DOI:10.1016/j.phrs.2019.104473.
   PubMed Web of Science ®Google Scholar
• Berekmeri A, Mahmood F, Wittmann M, et al. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719–730.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391(10136):2213–2224.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
   PubMed Web of Science ®Google Scholar
• Laterza OF, Hendrickson RC, Wagner JA. Molecular biomarkers. Drug Inf J. 2007;41(5):573–585.
   Google Scholar
• Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463–466.
   PubMed Web of Science ®Google Scholar
• Chandran V, Siannis F, Rahman P, et al. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol. 2010;37(7):1508–1512.
   PubMed Web of Science ®Google Scholar
• van Vugt LJ, JMPA VDR, Hannink G, et al. Association of HLA-C*06:02 status with differential response to Ustekinumab in patients with psoriasis: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(6):708–715.
   PubMed Web of Science ®Google Scholar
• Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120–2130.
   PubMed Web of Science ®Google Scholar
• Seitz M, Wirthmüller U, Möller B, et al. The −308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007;46(1):93–96.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gulli R, Spanò F, et al. TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. J Invest Dermatol. 2014;134(10):2503–2509.
   PubMed Web of Science ®Google Scholar
• Morales-Lara MJ, Cañete JD, Torres-Moreno D, et al. P. Joint Bone Spine. 2012;79(6):591–596.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Negrini S, Magnani O, et al. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis. Expert Opin Drug Saf. 2017;16(10):1173–1179.
   PubMed Web of Science ®Google Scholar
• Julià A, Rodríguez J, Fernández-Sueiro JL, et al. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. Pharmacogenomics. 2014;15(14):1763–1769.
   PubMed Web of Science ®Google Scholar
• Vageli DP, Exarchou A, Zafiriou E, et al. Effect of TNF-α inhibitors on transcriptional levels of pro-inflammatory interleukin-33 and Toll-like receptors-2 and −9 in psoriatic plaques. Exp Ther Med. 2015;10(4):1573–1577.
   PubMed Web of Science ®Google Scholar
• Skarmoutsou E, Trovato C, Granata M, et al. Biological therapy induces expression changes in Notch pathway in psoriasis. Arch Dermatol Res. 2015;307(10):863–873.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Matheson RT, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015;24(7):529–535.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145–54.e9.
   PubMed Web of Science ®Google Scholar
• Boutet MA, Nerviani A, Lliso-Ribera G, et al. Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis. Rheumatology (Oxford). 2019 Sep;3:kez358.
   Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018 Apr;141(4):1202–1207.
   PubMed Web of Science ®Google Scholar
• Evangelatos G, Fragoulis GE, Koulouri V, et al. MicroRNAs in rheumatoid arthritis: from pathogenesis to clinical impact. Autoimmun Rev. 2019;11:102391.
   Google Scholar
• Ciancio G, Ferracin M, Saccenti E, et al. Characterisation of peripheral blood mononuclear cell microRNA in early onset psoriatic arthritis. Clin Exp Rheumatol. 2017;35(1):113–121.
   PubMed Web of Science ®Google Scholar
• Pelosi A, Lunardi C, Fiore PF, et al. MicroRNA expression profiling in psoriatic arthritis. Biomed Res Int. 2018;2018:7305380.
   PubMed Web of Science ®Google Scholar
• Lin SH, Ho JC, Li SC, et al. MiR-146a-5p expression in peripheral CD14⁺ monocytes from patients with psoriatic arthritis induces osteoclast activation, bone resorption, and correlates with clinical response. J Clin Med. 2019;8(1):E110.
   PubMed Web of Science ®Google Scholar
• Chatzikyriakidou A, Voulgari PV, Georgiou I, et al. The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scand J Immunol. 2010;71(5):382–385.
   PubMed Web of Science ®Google Scholar
• Guinea-Viniegra J, Jiménez M, Schonthaler HB, et al. Targeting miR-21 to treat psoriasis. Sci Transl Med. 2014;6(225):225re1.
   PubMed Web of Science ®Google Scholar
• Meisgen F, Xu N, Wei T, et al. MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp Dermatol. 2012;21(4):312–314.
   PubMed Web of Science ®Google Scholar
• Løvendorf MB, Zibert JR, Gyldenløve M, et al. MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. J Dermatol Sci. 2014;75(2):133–139.
   PubMed Web of Science ®Google Scholar
• Pivarcsi A, Meisgen F, Xu N, et al. Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor-α therapy. Br J Dermatol. 2013;169(3):563–570.
   PubMed Web of Science ®Google Scholar
• Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159(2):322–330.
   PubMed Web of Science ®Google Scholar
• Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010;69(2):394–399.
   PubMed Web of Science ®Google Scholar
• Gratacós J, Casado E, Real J, et al. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis. 2007;66(4):493–497.
   PubMed Web of Science ®Google Scholar
• Wagner CL, Visvanathan S, Elashoff M, et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis. 2013;72(1):83–88.
   PubMed Web of Science ®Google Scholar
• Jensen P, Wiell C, Milting K, et al. Plasma YKL-40: a potential biomarker for psoriatic arthritis?. J Eur Acad Dermatol Venereol. 2013;27(7):815–819.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res. 2015;2015:906349.
   PubMed Web of Science ®Google Scholar
• Chandran V, Shen H, Pollock RA, et al. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. J Rheumatol. 2013;40(6):866–871.
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Ramirez J, Hernández MV, et al. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. Arthritis Res Ther. 2018;20(1):275.
   PubMed Web of Science ®Google Scholar
• Gibson DS, Rooney ME. The human synovial fluid proteome: a key factor in the pathology of joint disease. Proteomics Clin Appl. 2007;1(8):889–899.
   PubMed Web of Science ®Google Scholar
• Cretu D, Diamandis EP, Chandran V. Delineating the synovial fluid proteome: recent advancements and ongoing challenges in biomarker research. Crit Rev Clin Lab Sci. 2013;50(2):51–63.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Sfriso P, Oliviero F, et al. Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Arthritis Res Ther. 2010;12(4):R148.
   PubMed Web of Science ®Google Scholar
• Collins ES, Butt AQ, Gibson DS, et al. A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritis. Proteomics Clin Appl. 2016;10(6):645–662.
   PubMed Web of Science ®Google Scholar
• Ademowo OS, Hernandez B, Collins E, et al. Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. Ann Rheum Dis. 2016;75(1):234–241.
   PubMed Web of Science ®Google Scholar
• Pontifex EK, Gerlag DM, Gogarty M, et al. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy–a single centre, open-label study. Arthritis Res Ther. 2011;13(1):R7.
   PubMed Web of Science ®Google Scholar
• van Kuijk AW, Gerlag DM, Vos K, et al. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis. 2009;68(8):1303–1309.
   PubMed Web of Science ®Google Scholar
• Miyagawa I, Nakayamada S, Nakano K, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford). 2019;58(2):336–344.
   PubMed Web of Science ®Google Scholar
• Kell DB, Oliver SG. The metabolome 18 years on: a concept comes of age. Metabolomics. 2016;12:148.
   PubMed Web of Science ®Google Scholar
• Kapoor SR, Filer A, Fitzpatrick MA, et al. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65(6):1448–1456.
   PubMedGoogle Scholar
• Brusselaers N. PrescribedDrugs and the Microbiome. Gastroenterol Clin North Am. 2019;48(3):331–342.
   PubMed Web of Science ®Google Scholar
• Helmink BA, Khan MAW, Hermann A, et al. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25(3):377–388.
   PubMed Web of Science ®Google Scholar
• Sayers E, MacGregor A, Carding SR. Drug-microbiota interactions and treatment response: relevance to rheumatoid arthritis. AIMS Microbiol. 2018;4(4):642–654.
   PubMed Web of Science ®Google Scholar
• Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41(6):1212–1217.
   PubMed Web of Science ®Google Scholar
• Kerschbaumer A, Smolen JS, Aletaha D. Disease activity assessment in patients with psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):401–414.
   PubMed Web of Science ®Google Scholar
• Jadon DR, Chandran V, Ogdie A, et al. Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting. J Rheumatol Suppl. 2019;95:11–19.
   PubMedGoogle Scholar